Key Takeaways
- A class action lawsuit has been filed against Sana Biotechnology, Inc. for alleged securities fraud impacting investors from March 17, 2023, to November 4, 2024.
- The lawsuit claims that the company’s financial statements were misleading and did not reveal risks related to its product candidates and funding.
- Investors can apply to be lead plaintiffs by May 20, 2025, with no upfront costs to participate in the lawsuit for compensation.
Details of the Class Action Lawsuit
On March 27, 2025, Levi & Korsinsky, LLP announced a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA). This lawsuit intends to recover losses for investors affected by alleged securities fraud during the period from March 17, 2023, to November 4, 2024.
The complaint asserts that the defendants made several false statements and failed to disclose critical information, which misled investors. In particular, it is said that Sana Biotechnology was at substantial risk of lacking adequate funding to sustain its operations and progress its project candidates. The products SC291 in oncology, SC379, and SG299 were described as being less promising than had been previously communicated to investors.
Furthermore, the lawsuit indicates that in order to conserve cash and advance its more viable product candidates, Sana was likely planning to reduce funding for or discontinue SC291, SC379, and SG299, along with significant cuts to its workforce. Consequently, the defendants are accused of overstating the company’s financial health and operational capabilities, rendering their public statements misleading.
Investors who suffered losses during the specified period have until May 20, 2025, to express their interest in becoming lead plaintiffs. However, participation as a lead plaintiff is not necessary to receive compensation if the lawsuit is successful. Class members stand to gain without incurring any personal costs, as there are no fees or obligations to participate.
Levi & Korsinsky, LLP has a strong track record in securities litigation, securing compensation for shareholders over the past two decades. The firm’s extensive experience and size, with over 70 employees, underscore its capability in handling complex cases. For seven consecutive years, it has been recognized among the top securities litigation firms in the United States according to ISS Securities Class Action Services’ Top 50 Report.
For more information or to get in touch, investors can contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or call (212) 363-7500.
The content above is a summary. For more details, see the source article.